McKesson is essentially a giant delivery network for medicine. It picks up drugs from pharmaceutical manufacturers and moves them to pharmacies, hospitals, doctor offices, and clinics across the United States and Canada. Every time a drug moves through that network, McKesson earns a fee. The company also runs a fast-growing oncology business that supports cancer doctors and specialist clinics, a technology arm that helps patients afford and access their prescriptions, and a medical supplies division that ships gloves, syringes, and lab equipment to non-hospital settings. Revenue hit $403.4 billion in fiscal 2026, making McKesson one of the largest companies in America by sales. The diagram below traces where the money goes.
How McKesson Makes Money
flowchart LR
A["Healthcare Customers
403.4B revenue"] -->|"Drugs, supplies,
services"|B["Four Business
Segments"]
B -->|"Pharma distrib
& logistics"|C["North American
Pharmaceutical"]
B -->|"Oncology &
specialty care"|D["Oncology &
Multispecialty"]
B -->|"Tech solutions
& affordability"|E["Prescription
Technology"]
B -->|"Medical supplies
& equipment"|F["Medical-Surgical
Solutions"]
C -->|"Data, insights,
efficiency gains"|G["Customers Increase
Revenue & Margins"]
D -->|"Practice tools,
research, outcomes"|G
E -->|"10B savings,
650M prescriptions"|G
F -->|"270K products,
operational support"|G
G -->|"Repeat orders,
contract renewal"|A
A -->|"3.6% gross margin,
6.2B operating cash"|H["Reinvestment in
Distribution & Tech"]
H -->|"27 US centers,
automation, AI"|C
H -->|"Network expansion,
infusion clinics"|D
H -->|"EHR connections,
logistics scaling"|E
H -->|"336K customers,
4K branded products"|F
H -->|"Better capacity,
service quality"|A
Five years of financial data tell a consistent story: McKesson is getting bigger very fast, but each additional dollar of revenue comes with thinner profit margins. Revenue grew from $264.0 billion in fiscal 2022 to $403.4 billion in fiscal 2026, a gain of more than $139 billion in four years. That is remarkable scale. But gross margin compressed steadily across the same period, falling from roughly 5.0% in 2022 to 3.6% in 2026. In a business that moves nearly half a trillion dollars in product, even a small margin slip matters enormously in dollar terms.
McKesson Revenue 2022 to 2026 ($B)
Revenue has grown by more than $139 billion over four years, driven mainly by higher drug volumes through the North American Pharmaceutical segment.
Free cash flow tells a more reassuring story. It rose from $4.0 billion in fiscal 2022 to $5.7 billion in fiscal 2026, meaning the business actually converts more cash from its operations over time even as margins shrink. The company used $4.8 billion of that cash in fiscal 2026 alone to buy back its own shares, and it raised the quarterly dividend from $0.71 to $0.82 per share. Net debt swung between positive and negative across the five years, ending fiscal 2026 at $1.3 billion, which is a modest number relative to the cash the business generates annually.
$5.7B
Free cash flow in fiscal 2026, up from $4.0B in fiscal 2022
The fastest-growing part of the business is not the core pharmaceutical distribution network. It is the Oncology and Multispecialty segment, which grew revenues 31% in a single year to reach $48.4 billion in fiscal 2026. McKesson spent $875 million to acquire a controlling stake in PRISM Vision, a retina and eye care network, and $2.5 billion to acquire Core Ventures, a business services organization for a major Florida cancer practice. These moves signal that McKesson is building a connected system around cancer and specialty care, not just shipping drugs to pharmacies.
31%
Oncology and Multispecialty revenue growth in fiscal 2026, reaching $48.4B
2025
milestone
McKesson Breaks Up Its Own Business
In fiscal 2026, McKesson announced plans to spin off its Medical-Surgical Solutions segment into a fully independent company. That division sells over 270,000 products including gloves, needles, and lab supplies to more than 336,000 customers. Apollo Global Management agreed to pay $1.25 billion for a 13% stake in the segment as part of the separation plan. This suggests McKesson wants to focus tightly on pharmaceutical distribution and specialty care rather than running a broad medical supplies business alongside everything else.
The risks McKesson faces are specific and well-documented, not just generic business hazards. The most pressing involve money, licenses, and data. Start with customer concentration: the single largest customer accounts for 24% of total revenue. If that relationship weakens for any reason, a very large hole opens in the income statement. Then there is the regulatory question. McKesson operates under licenses issued by the DEA and FDA, plus state pharmacy boards in every state it serves. Those licenses can be revoked. Without them, McKesson cannot distribute drugs, which is the foundation of the entire business.
What Are Controlled Substance Monitoring Requirements?
The DEA requires drug distributors to track and report suspicious orders of drugs like opioids. McKesson must maintain expensive monitoring systems at all its distribution centers. Failing to meet these standards can result in fines or loss of the DEA registration that allows the company to ship controlled substances at all.
The opioid settlement history adds real weight to the regulatory risk. McKesson paid $13 million in fines in 2008 for opioid tracking failures, then $300 million in 2017 for similar violations, and then joined a $26 billion industry-wide settlement in 2022. These were not hypothetical problems. They were repeated failures that cost the company billions. Ongoing opioid-related claims still appear on the balance sheet, with a charge of $108 million recorded in fiscal 2025 alone for estimated future liabilities.
$26B
Multi-company opioid settlement McKesson joined in 2022 alongside other drug distributors
What Is the Inflation Reduction Act and Why Does It Matter Here?
The Inflation Reduction Act allows the federal government to negotiate prices for certain Medicare drugs directly with manufacturers. It also caps what patients pay out of pocket. Because McKesson earns fees based on drug transactions, changes to how drugs are priced and paid for can change how much McKesson earns on each transaction. The full impact is still working its way through the healthcare system.
Government policy adds a separate layer of uncertainty. The Inflation Reduction Act is already changing how Medicare pays for drugs. A new rule effective January 2026 requires drug manufacturers to get certifications from wholesalers like McKesson about how distribution fees are handled, creating a risk that existing service agreements get renegotiated. The One Big Beautiful Bill, enacted in July 2025, is expected to reduce Medicaid enrollment, which could shrink the pool of patients buying drugs through the channels McKesson serves. An executive order from May 2025 directs drug manufacturers to sell certain medicines in the United States at prices no higher than the lowest price in other developed countries, which could pressure the value of each transaction flowing through McKesson's network. Finally, a cyberattack on McKesson's systems would be uniquely dangerous: the company stores sensitive patient health information and manages supply chains that hospitals depend on daily.
McKesson's Prescription Technology Solutions segment helped patients save approximately $10 billion on brand and specialty medications in a single year and prevented an estimated 12 million prescriptions from being abandoned due to cost. That segment earned an operating margin of nearly 18%, far above the 1% margin of the core pharmaceutical distribution business. Size is not where the profit lives.
The Bet
McKesson's oncology and specialty care expansion has to generate rising profits fast enough to offset the structural compression in pharmaceutical distribution margins. The core distribution business moves enormous volumes but keeps only a thin slice of each transaction, and that slice has been shrinking every year for five consecutive years. If specialty care, technology solutions, and practice management grow their earnings as quickly as their revenues have grown, the business mix shifts toward higher-margin work and the overall profit picture improves. If pharmaceutical pricing reform or policy changes squeeze distribution fees further before the specialty platform matures, there is no obvious cushion to absorb it.
Open question
McKesson controls a genuinely difficult-to-replicate distribution network, earns growing free cash flow, and is deliberately reshaping itself around cancer care and specialty medicine. But its core drug distribution margins have compressed every year for five years, it relies on one customer for nearly a quarter of all revenue, and government policy is actively targeting the pharmaceutical pricing chain that funds the whole operation. Can the oncology and specialty care businesses grow their margins fast enough to replace what the core distribution network is quietly losing, before policy changes or customer concentration risks force the issue?
Compiled · 10-K · FY2026
